RMTG to Hold First-Ever Investor Call to Discuss Second Quarter 2026 Results
Rhea-AI Summary
Regenerative Medical Technologies Group (OTC:RMTG) plans to hold its first-ever investor call within the next two weeks to discuss what it describes as significant positive results expected in its upcoming Q2 2026 filing. The initiative is positioned as a milestone in shareholder engagement and transparency.
According to RMTG, Q1 2026 delivered record results: revenue of $2,639,353, up 93% year over year; gross profit of $1,766,491, up 87%; and operating income of $229,783, up 70%. Growth was led by the ISSCA training division, Cellgenic product supply, and recurring Affiliate membership revenue across a clinic network in more than 30 countries. Investors can submit questions via email this week, with a follow-up release to provide the call’s exact date, time, and dial-in details.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A Positive First Half of 2026 Prompts the Company to Launch Its First Investor Call and Invite Shareholder Questions
MIAMI, FL / ACCESS Newswire / August 5, 2026 / Regenerative Medical Technologies Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group, today announced that it expects to hold an investor call within the next two weeks to discuss significant positive results in connection with its upcoming Q2 2026 filing. The call - the first in the Company's history - reflects the success of RMTG's performance through the first half of 2026 and management's commitment to increased transparency and engagement with its shareholders.
A Milestone Moment for Shareholder Engagement
Why the Company Is Hosting Its First Investor Call
Following a strong start to 2026, management believes the Company has reached an inflection point worthy of direct engagement with the investment community. RMTG's first quarter demonstrated rapid, profitable growth, and the Company believes its second-quarter results will further underscore the momentum building across its global regenerative medicine platform. The investor call is intended to give shareholders a direct line to management ahead of the Q2 filing.
Building on a Strong First Quarter
As previously reported, RMTG delivered record results in the first quarter of 2026:
Revenue grew
93% year over year to$2,639,353 , compared to$1,364,341 in Q1 2025.Gross profit grew
87% to$1,766,491 , compared to$943,894 in the prior-year period.Operating income grew
70% to$229,783 , compared to$134,960 in Q1 2025.
Growth was led by the Company's ISSCA training division and its Cellgenic product-supply operation, supported by an expanding base of recurring Affiliate membership revenue and a global clinic network spanning more than 30 countries. Management looks forward to discussing how these trends carried into the second quarter on the upcoming call.
How Shareholders Can Participate
Investors are invited to submit questions in advance of the call throughout this week by emailing investor.relations@regenmedtechgroup.com. Management will endeavor to answer as many questions as practicable during the call.
The Company will issue a follow-up press release a few days before the investor call to specify the date, time, and dial-in details. The Company expects to provide additional updates on its growth initiatives and operating performance in subsequent releases and encourages investors and interested parties to review the Company's filings at www.sec.gov.
About Regenerative Medical Technologies Group, Inc.
Regenerative Medical Technologies Group, Inc. (OTC:RMTG) is a regenerative medicine company operating through Global Stem Cells Group and its subsidiaries, combining physician education, laboratory operations, biologics manufacturing, product commercialization, and digital healthcare technologies across an international network. The Company operates across more than 30 countries. Additional information about the Company's business, operations, and risks is available in its filings with the Securities and Exchange Commission.
Forward-Looking Statements
This press release contains forward-looking statements. These statements include, but are not limited to, the anticipated timing and holding of the Company's first investor conference call, the issuance of financial results for the second quarter ended June 30, 2026 prior to the call, and any statements regarding the Company's plans, expectations, or intentions with respect to the call or related disclosures. Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, the Company's ability to continue as a going concern, liquidity and capital resource constraints, substantial debt obligations and the risk of acceleration of such debt, regulatory developments and compliance requirements in the United States, Argentina and other jurisdictions, market acceptance of the Company's products and services, operational execution risks, competitive conditions, and the other risks described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and in its subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
###
Contact:
Investor Relations
Regenerative Medical Technologies Group, Inc.
investor.relations@regenmedtechgroup.com | (800) 956-3935
SOURCE: Regenerative Medical Technology Group
View the original press release on ACCESS Newswire